

Lepu Medical Technology (Beijing) Co., Ltd.

The First Quarter Report in 2024

The Company and all members of the Board of Directors warrant that the information disclosed is authentic, accurate and complete, and contains no false records, misleading statements or material omissions.

Hint of Important Contents:

1. The Board of Directors, the Board of Supervisors, directors, supervisors, and senior executives of the Company shall guarantee the truthfulness, accuracy and completeness of the content of the quarterly report, without any false records, misleading statements or material omissions, and also assume several and joint legal liabilities.
2. The head of the Company, person in charge of accounting and person in charge of accounting department (accounting supervisor) hereby declare that: the financial information disclosed in the quarterly report is true, accurate and complete.
3. Whether the Q1 Report has passed the audit
 Yes No

I. Key Financial Data

(I) Major accounting data and financial indexes

Whether the Company needs to retrospectively adjust or restate previous annual accounting data?

Yes No

	Current reporting period	Same period of last year	The increase/decrease of the report period from the same period of the previous year (%)
Operating income (RMB)	1, 922, 028, 839. 15	2, 437, 202, 386. 92	-21. 14%
Net profits attributable to shareholders of the listed companies (RMB)	481, 871, 134. 58	596, 924, 222. 49	-19. 27%
Net profits attributable to shareholders of the listed company after deducting non-recurring profits and losses (RMB)	456, 433, 815. 92	562, 429, 846. 30	-18. 85%
Net cash flow from operating activities (RMB)	141, 518, 257. 63	-134, 203, 435. 01	205. 45%
Basic earnings per share (RMB/share)	0. 2594	0. 3205	-19. 06%
Diluted earnings per share (RMB/share)	0. 2585	0. 3177	-18. 63%
Weighted average return on net assets	2. 98%	3. 86%	-0. 88%

	End of current reporting period	End of the last year	The increase/decrease of the report period from the end of the previous year (%)
Total assets (RMB)	25,508,525,579.77	25,022,331,486.69	1.94%
Owners' equities attributable to shareholders of the Company (RMB)	16,377,673,701.46	15,976,101,963.31	2.51%

From the end of the reporting period to the disclosure date of the quarterly report, whether the share capital of the Company has changed due to the issuance of new shares, additional issuance, allotment, equity incentive exercise, repurchase and other reasons and whether the share capital of the Company has affected the amount of owners' equity.

Yes No

	Current reporting period
Paid preferred stock dividend (RMB)	0.00
Paid interest of perpetual bonds (RMB)	0.00
Fully diluted earnings per share calculated in accordance with the latest capital stock (RMB/share)	0.2562

(II) Items and amounts of non-recurring profits or losses

Applicable Not applicable

Unit: RMB

Item	Amount in the current reporting period	Instruction
Profits and losses on disposal of non-current assets (including the write-off of provision for asset impairment)	-400,599.42	
Government subsidies included in current profits and losses (except for government subsidies closely related to the normal business operations of Company, in line with national policies and obtained according to established standards and having continuous influence on the profits and losses of the Company)	25,030,500.22	
Profit or loss on changes in fair values of held-for-trading financial assets and financial liabilities by non-financial enterprises and profit or loss obtained from disposal of financial assets and financial liabilities, except for effective hedging operations associated with the Company's normal operation	3,140,031.28	
Non-operating income and expenditure other than those mentioned above	-5,106,824.89	
Other items of profits and losses that meet the definition of non-recurring profits and losses	11,517,966.56	
Minus: Influenced amount of income tax	3,796,220.51	
Influenced amount of minority shareholders' equities (after-tax)	4,947,534.58	
Total	25,437,318.66	--

Details of other profit and loss items complying with the definition of non-recurring profits or losses

Applicable Not applicable

The Company has no details of other profit and loss items complying with the definition of non-recurring profits or losses

Description on situations for defining non-recurring profit and loss items listed in the *Explanatory Announcement No.1 on Disclosure of the Information of Companies Offering Their Securities to the Public - Non-recurring Profits and Losses* as recurring profits and losses.

Applicable Not applicable

The Company has no situations for defining non-recurring profit and loss items listed in the *Explanatory Announcement No.1 on Disclosure of the Information of Companies Offering Their Securities to the Public - Non-recurring Profits and Losses* as recurring profits and losses.

(III) Details and reasons of changes of major accounting data and financial indexes

Applicable Not applicable

1. During the reporting period, the Company's operating income was RMB 1922.0288 million with a year-on-year decrease of 21.14% and a month-to-month increase of 11.70% compared with 2323Q4. The main reason for the year-on-year decrease in income was that some emergency products were still sold last year, and they were concentrated in Q1. The income of each business sector is as follows:

1) The operating income of medical devices reached RMB 885.6198 million, with a year-on-year decrease of 18.69% and a month-to-month increase of 9.22%. Wherein, the innovative product portfolio of cardiovascular intervention achieved a year-on-year increase of 19.92%. The income of important sub-sectors in medical device business is as follows:

Coronary intervention business: The operating income reached RMB 438.0181 million, with a year-on-year increase of 5.80% and a month-to-month increase of 22.17%.

Structural heart disease business: The operating income reached RMB 112.7253 million, with a year-on-year increase of 66.77% and a month-to-month increase of 45.45%.

Surgical anesthesia business: The operating income reached RMB 136.6886 million, with a year-on-year increase of 10.24% and basically unchanged month-to-month increase.

In vitro diagnosis business: The operating income reached RMB 110.3790 million, with a year-on-year decrease of 69.53%, caused by high base due to sales of emergency products in the same period of the last year, and with a month-to-month increase of 6.30%.

2) The operating income of pharmaceutical reached RMB 792.9157 million, with a year-on-year decrease of 15.69% and a month-to-month increase of 26.35%. The operating income of active pharmaceutical ingredients reached RMB 102.4139 million, with a year-on-year increase of

19.15%; The operating income of preparations reached RMB 690.5018 million, with a year-on-year decrease of 19.19%;

3) The operating income of medical service and health management reached RMB 243.4933 million, with a year-on-year decrease of 40.26%, caused by high base due to emergency products in the same period of the last year, and with a month-to-month decrease of 13.73%. Wherein, the operating income of Hefei Cardiovascular Hospital reached RMB 38.2155 million, with a year-on-year increase of 13.58%.

2. During the reporting period, the Company achieved a net profit of RMB 492.7605 million, with a year-on-year decrease of 20.31%; Net profit attributable to shareholders of the Company was RMB 481.8711 million, with a year-on-year decrease of 19.27%; The net profit attributable to shareholders of listed companies after non-recurring profits and losses were deducted was RMB 456.4338 million, with a year-on-year decrease of 18.85%, and the total non-recurring profits and losses was RMB 25.4373 million, mainly due to the decrease in government subsidies received.

3. During the reporting period, under the premise of not affecting the innovation and development, the Company continued to advocate and implement refined management, specialized operation and intensive development from top to bottom. After the equity incentive expenses were excluded, the sales expenses and management expenses had a year-on-year decrease of about 20%, and the research and development expenses had a slight year-on-year decrease of 9%. The financial expense was RMB 0.8698 million, with a year-on-year decrease of 98.40%, mainly due to the exchange loss of RMB 43.5413 million, in the same period of last year and the exchange gain of RMB 13.0605 million during the reporting period.

4. During the reporting period, the Company's investment loss was RMB 4.2926 million, with a year-on-year decrease of RMB 17.2503 million, decreased by 80.07% mainly due to the Company's step-by-step acquisition of the equity of Shanghai Minwei Biotechnology Co., Ltd. during the reporting period, the confirmed investment income was RMB 11.5703 million.

5. During the reporting period, the Company's earnings from the change in the fair value was RMB 3.4161 million, had a year-on-year decrease of RMB 2.3435 million or 40.69%, mainly due to changes in the market value of wealth management products held by the Company during the reporting period.

6. During the reporting period, the Company's non-operating income was RMB 7.1293 million, with a year-on-year decrease of RMB 26.0330 million or 78.50%, mainly due to the decrease in government incentives received by the Company during the reporting period.

7. During the reporting period, the Company's minority shareholders' profit and loss was RMB 10.8894 million, with a year-on-year decrease of RMB 10.5048 million or 49.10%, mainly due to performance disturbance of non-wholly-owned subsidiaries of the Company during the reporting period.

8. During the reporting period, the net inflow of cash flow generated by the Company's operating activities was RMB 141.5183 million, RMB 275.7217 million higher than that in the same period of the last year, and the net inflow increased by RMB 134.2034 million with an increase of 205.45%, mainly due to the cash flow disturbance of unconventional business in the same period of last year.

9. During the reporting period, the net outflow of cash flow from the Company's financing activities was RMB 52.0621 million, while the net inflow was RMB 250.4781 million in the same period of last year, mainly due to the decrease of RMB 133.4131 million in the net inflow of loans, the increase of RMB 48.4918 million in the expenditure on the acquisition of minority shareholders' equity and the RMB 70.7418 million paid for repurchase of treasury shares.

10. At the end of the reporting period, the Company's salary payable to employees was RMB 58.2219 million with a decrease of RMB 46.5960 million or 44.45% compared with those at the beginning of the year, mainly due to the Company's payment of the bonus accrued in the previous year during the reporting period.

II. Information of Shareholders

(I) Table of Total Number of Common Shareholders and Preferred Shareholders Recovering Voting Rights and Shareholdings of Top Ten Shareholders

Unit: Share						
Total number of common shareholders at the end of the reporting period		91,316	Total number of preferred shareholders recovering voting rights at the end of reporting period (if any)		0	
Shareholding status of the top ten shareholders (excluding shares lent through transfer financing business)						
Name of shareholder(s)	Nature of shareholder(s)	Shareholding proportion (%)	Number of shares held	Number of shares held with restricted conditions	Pledge, marking or freezing information	
					Share status	Quantity

Luoyang Ship Material Research Institute	State-owned legal person	12.98%	244,063,788.00	0.00	N/A	
PU Zhongjie	Domestic natural person	12.13%	228,074,749.00	171,056,062.00	Pledge	157,349,999.00
WP MEDICAL TECHNOLOGIES, INC	Foreign legal person	6.59%	123,968,600.00	92,976,450.00	Pledge	71,050,000.00
Houde Yimin (Beijing) Investment Management Co., Ltd.	Domestic non-state-owned legal person	3.60%	67,750,000.00	0.00	N/A	
Hong Kong Securities Clearing Company Limited	Foreign legal person	2.51%	47,150,904.00	0.00	N/A	
Bank of China Limited - Huabao CSI medical trading open-end index securities investment fund	Others	2.04%	38,378,618.00	0.00	N/A	
Houde Yimin (Ningbo) Investment Management Co., Ltd.	Domestic non-state-owned legal person	1.91%	35,850,000.00	0.00	N/A	
China Construction Bank Corporation - mixed securities investment fund for China-Europe pension industry	Others	1.49%	28,115,009.00	0.00	N/A	
Industrial and Commercial Bank of China Limited - Yifangda Growth Enterprises Market open-end index securities investment fund	Others	1.36%	25,572,228.00	0.00	N/A	
Agricultural Bank of China Limited - China	Others	0.82%	15,443,740.00	0.00	N/A	

Securities 500 open-end index securities investment fund					
Shareholding of the top 10 shareholders with non-restricted conditions					
Name of shareholder(s)	Number of shares held without restricted conditions	Type of shares			
		Type of shares	Quantity		
Luoyang Ship Material Research Institute	244,063,788.00	RMB common share	244,063,788.00		
Houde Yimin (Beijing) Investment Management Co., Ltd.	67,750,000.00	RMB common share	67,750,000.00		
PU Zhongjie	57,018,687.00	RMB common share	57,018,687.00		
Hong Kong Securities Clearing Company Limited	47,150,904.00	RMB common share	47,150,904.00		
Bank of China Limited - Huabao CSI medical trading open-end index securities investment fund	38,378,618.00	RMB common share	38,378,618.00		
Houde Yimin (Ningbo) Investment Management Co., Ltd.	35,850,000.00	RMB common share	35,850,000.00		
WP MEDICAL TECHNOLOGIES, INC	30,992,150.00	RMB common share	30,992,150.00		
China Construction Bank Corporation - mixed securities investment fund for China-Europe pension industry	28,115,009.00	RMB common share	28,115,009.00		
Industrial and Commercial Bank of China Limited - Yifangda Growth Enterprises Market open-end index securities investment fund	25,572,228.00	RMB common share	25,572,228.00		
Agricultural Bank of China Limited - China Securities 500 open-end index securities investment fund	15,443,740.00	RMB common share	15,443,740.00		
Description of associated relationships or concerted actions of the above shareholders	Mr. PU Zhongjie, WP Medical Technologies, Inc., Houde Yimin (Beijing) Investment Management Co., Ltd. and Houde Yimin (Ningbo) Investment Management Co., Ltd. were persons acting in concert within the meaning of PRC law. There was no relationship between other shareholders of the Company or concerted action as stipulated in Measures for the Administration of Acquisition of Listed Companies (Order No.35 of China Securities Regulatory Commission).				
Description of the top 10 shareholders participating in financing and securities business (if any)	None				

Shareholders holding more than 5% of shares, the top 10 shareholders and the top 10 shareholders with unrestricted shares participating in the refinancing business to lend shares

Applicable Not applicable

Unit: Share

Shareholders holding more than 5% of shares, the top 10 shareholders and the top 10 shareholders with unrestricted shares participating in the refinancing business to lend shares				
Name of shareholder (full name)	Beginning ordinary accounts and credit account	Shares loaned for transfer financing business that have not yet been returned at beginning of the period	Ending ordinary accounts and credit account	Shares loaned for transfer financing business that have not yet been returned at ending of the period

	Total quantity	Proportion to general capital	Total quantity	Proportion to general capital	Total quantity	Proportion to general capital	Total quantity	Proportion to general capital
Industrial and Commercial Bank of China Limited - Yifangda Growth Enterprises Market open-end index securities investment fund	18,199,619	0.97%	41,900	0.00%	25,572,228	1.36%	42,300	0.00%
Bank of China Limited - Huabao CSI medical trading open-end index securities investment fund	39,250,818	2.09%	52,800	0.00%	38,378,618	2.04%	331,600	0.02%

Top 10 shareholders and the top 10 shareholders with unrestricted shares changed from the previous period due to lending/returning of refinancing

Applicable Not applicable

(II) Table of Total Number of the Preferred Shareholders and Shareholdings of Top 10 Preferred Shareholders of the Company

Applicable Not applicable

(III) Statement of restricted share change

Applicable Not applicable

Unit: Share

Name of shareholder(s)	Quantity of restricted stocks at the beginning of the period	Quantity of stocks removed with restrictions on sales in current period	Quantity of stocks increased with restrictions on sales in current period	Quantity of restricted stocks at the end of the period	Reason for restriction on sales	Date of cancellation of the restriction
PU Zhongjie	171,056,062.00	0.00	0.00	171,056,062.00	Restricted circulation stock held by senior executives	During Mr. PU Zhongjie's employment in the Company, the annual

						transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after his resignation.
WP MEDICAL TECHNOLOGIES, INC	92,976,450.00	0.00	0.00	92,976,450.00	Pre-sale restricted shares	During Mr. PU Zhongjie's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after his resignation.
ZHANG Zhibin	163,125.00	0.00	0.00	163,125.00	Restricted circulation stock held by senior executives	During Mr. ZHANG Zhibin's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after his resignation.
WEI Zhanjiang	145,200.00	0.00	0.00	145,200.00	Restricted circulation stock held by senior executives	During Mr. WEI Zhanjiang's employment in the Company, the annual transfer of shares does not

						exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after his resignation.
WANG Yong	143,775.00	0.00	0.00	143,775.00	Restricted circulation stock held by senior executives	During Ms. WANG Yong's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and she will not transfer the shares of the Company within half a year after his resignation.
FENG Xiaoying	5,550.00	0.00	0.00	5,550.00	Restricted circulation stock held by senior executives	During Ms. FENG Xiaoying's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and she will not transfer the shares of the Company within half a year after his resignation.
ZHENG Guorui	22,500.00	0.00	0.00	22,500.00	Restricted circulation stock held by senior executives	During Mr. ZHENG Guorui's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares

						of the Company, and he will not transfer the shares of the Company within half a year after his resignation.
Total	264,512,662.00	0.00	0.00	264,512,662.00		

III. Other Major Events

Applicable Not applicable

1. A disposable intracoronary shock wave catheter independently developed by the Company was officially approved by the National Medical Products Administration (NMPA) and obtained the Class III medical device registration certificate with the registration number: GXZZ 20243010074. (Announcement No.: 2024-005)

2. A coronary mastoid process balloon dilating catheter independently developed by the Company was officially approved by the National Medical Products Administration (NMPA) and obtained the Class III medical device registration certificate with the registration number: GXZZ 20243030105. (Announcement No.: 2024-007)

3. Oseltamivir phosphate dry suspension independently developed by Lepu Pharmaceutical Technology Co., Ltd., a subsidiary of the Company, was officially registered and approved by National Medical Products Administration (NMPA), with the drug approval number: GYZ Zi H20243080 (2024-008)

4. The subordinate companies Lepu Pharmaceuticals Co., Ltd. and Lepu Pharmaceutical Technology Co., Ltd. participated in the bidding for the centralized volume-based procurement of amoxicillin and other drugs in Guangdong Alliance. Clopidogrel bisulfate tablets, atorvastatin calcium tablets and rosuvastatin calcium tablets that had passed the consistency evaluation of generic drug quality and efficacy were intended to win the bid for this centralized procurement. (Announcement No.: 2024-010)

5. The GLP-1/GCGR/GIP-Fc fusion protein MWN101 independently developed by Shanghai Minwei Biotechnology Co., Ltd., a holding subsidiary of the Company, is carrying out two phase II clinical trials for treating type 2 diabetes and obesity or overweight, and each has successfully completed the first administration to subjects. (Announcement No.: 2024-019)

IV. Quarterly Financial Statements

(I) Financial statements

1. consolidated balance sheet

Prepared by: Lepu Medical Technology (Beijing) Co., Ltd.

Unit: RMB

Item	Ending balance	Beginning balance
Current assets:		
Monetary capital	4,130,387,971.16	4,220,754,806.78
Deposit reservation for balance		
Lending funds		
Trading financial assets	269,236,747.21	275,203,779.61
Derivative financial assets		
Notes receivable	93,222,618.10	84,509,973.95
Accounts receivable	2,129,677,788.22	1,753,160,708.35
Receivables financing	63,430,547.46	83,407,668.79
Advance payment	336,788,491.21	320,471,238.27
Premium receivable		
Reinsurance accounts receivable		
Reserves for reinsurance contract receivable		
Other receivables	141,269,677.09	110,449,885.41
Including: Interests receivable		
Dividends receivable		
Redemptory monetary capital for sale		
Inventory	2,217,579,109.36	2,289,473,586.38
Including: Data resource		
Contract assets		
Held-for-sale assets		
Non-current assets due within one year	3,073,459.03	3,302,070.61
Other current assets	227,640,229.15	184,703,896.89
Total current assets	9,612,306,637.99	9,325,437,615.04
Non-current assets:		
Loan granted and advances		
Creditor's right investments		
Other creditor's right investments		
Long-term receivables	2,823,890.12	2,968,556.17
Long-term equity investments	1,235,445,532.51	1,353,760,737.79
Other equity instrument investments	1,196,114,263.89	1,190,240,450.59
Other non-current financial assets	26,500,000.00	26,500,000.00
Investment property	295,172,834.84	296,774,138.94
Fixed assets	2,780,381,468.61	2,812,962,375.74
Engineering in progress	1,835,244,469.53	1,797,285,664.72
Productive biological assets		
Oil-gas assets		
Right-of-use assets	355,119,435.28	326,430,233.20
Intangible assets	1,760,286,299.64	1,817,546,203.28
Including: Data resource		
Development expenditures	907,248,638.04	861,745,696.38
Including: Data resource		
Goodwill	3,752,478,309.76	3,504,330,628.08

Long-term unamortized expenses	279,566,936.64	256,771,874.86
Deferred income tax assets	160,282,878.65	167,324,190.66
Other non-current assets	1,309,553,984.27	1,282,253,121.24
Total non-current assets	15,896,218,941.78	15,696,893,871.65
Total assets	25,508,525,579.77	25,022,331,486.69
Current liabilities:		
Short-term borrowings	1,172,306,616.94	1,039,743,103.15
Borrowings from the central bank		
Borrowing funds		
Trading financial liabilities		
Derivative financial liabilities		
Notes payable	129,357,261.29	167,917,721.65
Accounts payable	773,980,501.61	861,366,956.73
Advance receipt		
Contract liabilities	252,964,296.82	269,519,519.47
Financial assets sold for repurchase		
Deposits from customers and interbank		
Acting trading securities		
Acting underwriting securities		
Employee remuneration payable	58,221,886.78	104,817,928.71
Taxes payable	273,125,387.05	199,105,826.66
Other payables	521,765,382.49	555,678,277.77
Including: Interests payable		
Dividends payable	3,353,503.56	3,353,503.56
Fees and commissions payable		
Reinsurance accounts payable		
Held-for-sale liabilities		
Non-current liabilities due within one year	426,360,695.78	498,035,202.06
Other non-current liabilities	61,837,673.54	62,471,403.25
Total non-current liabilities	3,669,919,702.30	3,758,655,939.45
Non-current liabilities:		
Reserves for insurance contract		
Long-term borrowings	1,621,958,601.67	1,542,190,754.84
Bonds payables	1,560,193,176.69	1,560,810,898.63
Including: Preferred shares		
Perpetual bonds		
Lease liabilities	293,163,712.88	269,967,672.04
Long-term payables		
Long-term employee remuneration payable		
Estimated liabilities		
Deferred incomes	152,908,690.26	195,216,181.81
Deferred income tax liabilities	200,610,810.10	197,934,919.32
Other current liabilities		
Total current liabilities	3,828,834,991.60	3,766,120,426.64
Total liabilities	7,498,754,693.90	7,524,776,366.09
Owners' equities:		
Share capital	1,880,610,488.00	1,880,610,352.00
Other equity instruments	214,750,537.10	214,751,048.51
Including: Preferred shares		
Perpetual bonds		
Capital reserves	3,461,952,337.45	3,464,665,903.83
Minus: Treasury shares	505,766,649.73	431,064,877.67
Other comprehensive incomes	-83,667,785.02	-80,892,863.74
Special reserves		

Surplus reserves	732,541,206.45	732,541,206.45
General risk reserves		
Undistributed profits	10,677,253,567.21	10,195,491,193.93
Total owners' equities attributable to the parent company	16,377,673,701.46	15,976,101,963.31
Minority equity	1,632,097,184.41	1,521,453,157.29
Total owners' equities	18,009,770,885.87	17,497,555,120.60
Total liabilities and owner's equities	25,508,525,579.77	25,022,331,486.69

Legal representative: Pu Zhongjie Chief Financial Officer: Wang Yong Accounting Manager: Li Yun

2. Consolidated Profit Statement

Unit: RMB

Item	Accrual in the current period	Accrual in the last period
I. Total operating income	1,922,028,839.15	2,437,202,386.92
Including: Operating incomes	1,922,028,839.15	2,437,202,386.92
Interest incomes		
Earned premium		
Incomes from fees and commissions		
II. Total operating costs	1,336,348,890.00	1,749,019,988.44
Including: Operating cost	636,463,766.47	805,474,394.75
Interest expenditure		
Expenditures from fees and commissions		
Surrender value		
Net amount of compensation payout		
Withdrawal of net amount of reserve fund for insurance liabilities		
Bond insurance expense		
Reinsurance expenses		
Taxes and surcharges	24,345,130.02	24,992,941.86
Sales expense	334,350,310.50	440,814,329.67
Management expense	142,934,575.75	193,623,961.57
R&D expenses	197,385,261.91	229,686,257.30
Financial expense	869,845.35	54,428,103.29
Including: Interest expenses	42,207,977.95	43,468,101.66
Interest incomes	29,411,929.40	34,161,881.52
Plus: Other incomes	21,519,244.45	25,753,889.40
Return on investment (the loss is expressed with "-")	-4,292,647.74	-21,542,984.71
Including: Return on investment in associated enterprises and joint ventures	-15,814,845.75	-19,822,646.61
Income from derecognition of financial assets measured at amortized cost		
Foreign exchange gains (the loss)		

is expressed with "-")		
Income from net exposure hedging (the loss is expressed with "-")		
Income from change in fair value (the loss is expressed with "-")	3,416,117.92	5,759,598.45
Credit impairment loss (the loss is expressed with "-")	3,627,336.50	-440,479.31
Asset impairment loss (the loss is expressed with "-")	-328,202.44	877,615.53
Income from asset disposal (the loss is expressed with "-")	-400,599.42	1,253,000.35
III. Operating profit (the loss is expressed with "-")	609,221,198.42	699,843,038.19
Plus: Non-operating incomes	7,129,312.85	33,162,344.03
Minus: Non-operating expenditures	9,139,008.43	2,046,253.57
IV. Total profits (the total losses are expressed with "-")	607,211,502.84	730,959,128.65
Minus: Income tax expense	114,450,959.38	112,640,660.86
V. Net profit (the loss is expressed with "-")	492,760,543.46	618,318,467.79
(I) Classified by operation continuity		
1. Net profit from continuing operation (the net loss is expressed in with "-")	492,760,543.46	618,318,467.79
2. Net profit from discontinuing operation (the net loss is expressed in with "-")		
(II) Classification by ownership		
1. Net profits attributable to the owners of the parent company	481,871,134.58	596,924,222.49
2. Minority shareholders' profit and loss	10,889,408.88	21,394,245.30
VI. After-tax net amount of other comprehensive incomes	-8,798,240.24	38,892,944.33
After-tax net amount of other comprehensive incomes attributable to the owners of the parent company	-2,883,682.58	41,769,312.15
(I) Other comprehensive incomes that cannot be reclassified into profits and losses	13,164,998.13	33,688,592.78
1. Re-measurement of changed amount in the defined benefit plan		
2. Other comprehensive incomes that cannot be transferred into the profits and losses under the equity method		
3. Changes in fair value of other equity instrument investments	13,164,998.13	33,688,592.78
4. Changes in fair value of enterprise credit risk		
5. Others		
(II) Other comprehensive incomes that can be reclassified into profits and losses	-16,048,680.71	8,080,719.37
1. Other comprehensive incomes that can be transferred into the profits and losses under the equity method	-9,038.71	31,111.93

2. Changes in fair value of other creditor's right investments		
3. Amounts of financial assets reclassified into other comprehensive incomes		
4. Credit impairment reserves of other creditor's right investments		
5. Cash flow hedging reserves		
6. Translation difference of foreign currency financial statements	-16,039,642.00	8,049,607.44
7. Others		
After-tax net amount of other comprehensive incomes attributable to the minority shareholders	-5,914,557.66	-2,876,367.82
VII. Total comprehensive incomes	483,962,303.22	657,211,412.12
Total comprehensive incomes attributable to the owners of the parent company	478,987,452.00	638,693,534.64
Total comprehensive incomes attributable to minority shareholders	4,974,851.22	18,517,877.48
VIII. Earnings per share:		
(I) Basic earnings per share	0.2594	0.3205
(II) Diluted earnings per share	0.2585	0.3177

As for the business combination under the same control in the current period, net profits achieved by the combined party before the combination was:0.00 RMB , and the net profit achieved by the combined party for the last period is:0.00 RMB

Legal representative: Pu Zhongjie Chief Financial Officer: Wang Yong Accounting Manager: Li Yun

3. Consolidated Cash Flow Statement

Unit: RMB

Item	Accrual in the current period	Accrual in the last period
I. Cash flow generated from operating activities:		
Cash received from the sales of goods or rendering of services	1,636,352,953.22	2,221,855,789.57
Net increase of deposits from customers and other banks		
Net increase in borrowings from the central bank		
Net increase in borrowing funds from other financial institutions		
Cash received from the original insurance contract premium		
Net cash received from reinsurance premiums		
Net increase in policy holder deposits and investment funds		
Cash received from interests, fees and commissions		
Net increase in borrowing funds		
Net increase in repurchase business funds		
Net cash received from vicariously traded securities		

Refund of taxes and fees received	25,176,943.60	46,248,595.98
Other cash received related to operating activities	52,192,717.42	52,383,241.05
Subtotal of cash inflow from operating activities	1,713,722,614.24	2,320,487,626.60
Cash paid for purchase of goods or rendering of services	453,575,260.63	898,115,503.14
Net increase in customer loans and advances		
Net increase of deposits in central bank and other banks		
Cash paid for indemnity of original insurance contract		
Net increase in lending funds		
Cash received from interests, fees and commissions		
Cash paid for policy dividends		
Cash paid to and for employees	549,394,164.36	715,632,096.89
Various taxes and dues paid	261,391,946.90	392,054,371.25
Other cash paid related to operating activities	307,842,984.72	448,889,090.33
Subtotal of cash outflow from operating activities	1,572,204,356.61	2,454,691,061.61
Net cash flow from operating activities	141,518,257.63	-134,203,435.01
II. Cash flow generated from investing activities:		
Cash received from withdrawing investment	162,587,386.56	279,402,015.38
Cash received from obtaining return on investment	2,613,039.56	9,775,641.60
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	20,649,106.20	63,808.20
Net cash received from disposal of subsidiaries and other business units	15,250,149.21	
Other cash received related to investing activities	9,190,500.93	600,000.00
Subtotal of cash inflow from investing activities	210,290,182.46	289,841,465.18
Net cash paid for purchase and construction of fixed assets, intangible assets and other long-term assets	144,125,931.38	210,645,996.42
Cash paid for investment	156,311,060.73	260,817,249.97
Net increase in pledged loans		
Net cash paid for disposal of subsidiaries and other business entity	20,000,000.00	
Other cash received related to investing activities	169,870,093.99	30,788,197.13
Subtotal of cash outflow from investing activities	490,307,086.10	502,251,443.52
Net cash flow from investing activities	-280,016,903.64	-212,409,978.34
III. Cash flow generated from financing activities:		
Cash received from attracting		431,940.00

investment		
Including: Cash received by subsidiaries from absorbing investments from minority shareholders		431,940.00
Cash received from borrowings	634,086,899.50	617,000,000.00
Other cash received related to financing activities	12,590,667.92	38,987,595.51
Subtotal of cash inflow from financing activities	646,677,567.42	656,419,535.51
Cash paid for repaying debts	478,000,000.00	327,500,000.00
Cash paid for the distribution of dividends, profits or repayment of interests	38,686,008.93	23,452,766.31
Including: Dividends and profits paid to minority shareholders by subsidiaries		
Other cash received related to financing activities	182,053,706.15	54,988,625.07
Subtotal of cash outflow from financing activities	698,739,715.08	405,941,391.38
Net cash flow from financing activities	-52,062,147.66	250,478,144.13
IV. Effect of changes in exchange rate on cash and cash equivalents	1,664,154.20	-42,618,023.43
V. Net increase in cash and cash equivalents	-188,896,639.47	-138,753,292.65
Plus: Balance of cash and cash equivalents at the beginning of the period	4,099,954,989.87	5,309,297,789.78
VI. Balance of cash and cash equivalents at the end of the period	3,911,058,350.40	5,170,544,497.13

(II) Implementation of the adjustment of new accounting standards, and the financial statement related items at the beginning of the year for the first time from 2024

Applicable Not applicable

(III) Audit report

Whether the Q1 Report has passed the audit

Yes No

The Company's Q1 Report has not been audited.

Board of Directors of Lepu Medical Technology (Beijing) Co., Ltd.

Apr. 19, 2024